Vor BioPharma

Q2 FY2026 EarningsQ2 FY26 missed consensus across bottom-line metrics, reporting a GAAP net loss of -$62.8M vs. -$35.5M expected, and a GAAP EPS of -$1.16 vs. -$0.70 expected. As a clinical-stage biotech, zero revenue was in-line with expectations. The deviation was primarily driven by elevated stock-based compensation and commercial readiness expenses, though the cash position remains solid at $466.1M with a runway extended into early 2029.